KRAS and cancer: Patients with KRAS WT cancer received for 2L treatment, in order of frequency, CIT alone (56.9%), chemotherapy alone (34.8%), and combination CIT and chemotherapy (8.3%); this pattern of results was similar in the 2L setting in patients with KRAS G12C–positive cancer (59.0, 35.5, and 5.6%, respectively; Table 1).